Genome-wide association study of response to methylphenidate in 187 children with attention-deficit/hyperactivity disorder

American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics

Volumn 147, Issue 8, 2008, Pages 1412-1418

  Mick, Eric ^a,b,g   Neale, Benjamin ^b,c,d   Middleton, Frank A ^e   McGough, James J ^f   Faraone, Stephen V ^e  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^e SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g NONE   (United States)

Author keywords

ADHD; Genomewide association study; Methylphenidate; Pharmacogenomic

Indexed keywords

DNA; METABOTROPIC RECEPTOR 7; METHYLPHENIDATE; NORADRENALIN TRANSPORTER;

ARTICLE; ATTENTION DEFICIT DISORDER; BRAIN REGION; CHILD; CLINICAL TRIAL; COMPUTER PROGRAM; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA EXTRACTION; DRUG DOSE TITRATION; FEMALE; GENOME; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NORADRENERGIC SYSTEM; PRIORITY JOURNAL; QUALITY CONTROL; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 57349087268     PISSN: 15524841     EISSN: 1552485X     Source Type: Journal    
DOI: 10.1002/ajmg.b.30865     Document Type: Article

References (37)

1. Adams J, Crosbie J, Wigg K, Ickowicz A, Pathare T, Roberts W, Malone M, Schachar R, Tannock R, Kennedy JL, et al. 2004. Glutamate receptor, ionotropic, N-methyl D-aspartate 2A (GRIN2A) gene as a positional candidate for attention-deficit/hyperactivity disorder in the 16p13 region. Mol Psychiatry 9(5):494-499.
2. Asghari V, Sanyal S, Buchwaldt S, Paterson A, Jovanovic V, Van Tol HH. 1995. Modulation of intracellular cyclic AMP levels by different human dopamine D4 receptor variants. J Neurochem 65(3):1157-1165.
3. Brookes K, Xu X, Chen W, Zhou K, Neale B, Lowe N, Anney R, Franke B, Gill M, Ebstein R, et al. 2006. The analysis of 51 genes in DSM-IV combined type attention deficit hyperactivity disorder: Association signals in DRD4, DAT1 and 16 other genes. Mol Psychiatry 11(10):934-953.
4. Cheon KA, Ryu YH, Kim JW, Cho DY. 2005. The homozygosity for 10-repeat allele at dopamine transporter gene and dopamine transporter density in Korean children with attention deficit hyperactivity disorder: Relating to treatment response to methylphenidate. Eur Neuropsychopharmacol 15(1):95-101.
5. Cheon KA, Kim BN, Cho SC. 2007. Association of 4-repeat allele of the dopamine D4 receptor gene exon III polymorphism and response to methylphenidate treatment in Korean ADHD children. Neuropsychopharmacology 32(6):1377-1383.
6. da Silva TL, Pianca TG, Roman T, Hutz MH, Faraone SV, Schmitz M, Rohde LA. 2008. Adrenergic alpha2A receptor gene and response to methylphenidate in attention-deficit/hyperactivity disorder-predominantly inattentive type. J Neural Transm 115(2):341-345.
7. Dudbridge F, Gusnanto A. 2008. Estimation of significance thresholds for genomewide association scans. Genet Epidemiol 32(3):227-234.
8. Faraone SV, Perlis RH, Doyle AE, Smoller JW, Goralnick J, Holmgren MA, Sklar P. 2005. Molecular genetics of attention deficit hyperactivity disorder. Biol Psychiatry 57(11):1313-1323.
9. Findling RL, Bukstein OG, Melmed RD, Lopez FA, Sallee FR, Arnold LE, Pratt RD. 2008. A randomized, double-blind, placebo-controlled, parallel-group study of methylphenidate transdermal system in pediatric patients with attention-deficit/hyperactivity disorder. J Clin Psychiatry 69(1):149-159.
10. Hamarman S, Fossella J, Ulger C, Brimacombe M, Dermody J. 2004. Dopamine receptor 4 (DRD4) 7-repeat allele predicts methylphenidate dose response in children with attention deficit hyperactivity disorder: A Pharmacogenetic Study. J Child Adolesc Psychopharmacol 14(4):564-574.
11. Joober R, Grizenko N, Sengupta S, Amor LB, Schmitz N, Schwartz G, Karama S, Lageix P, Fathalli F, Torkaman-Zehi A, et al. 2007. Dopamine transporter 3′-UTR VNTR genotype and ADHD: A pharmaco-behavioural genetic study with methylphenidate. Neuropsychopharmacology 32(6):1370-1376.
12. Kim JW, Biederman J, McGrath CL, Doyle AE, Mick E, Fagerness J, Purcell S, Smoller JW, Sklar P, Faraone SV. 2008. Further evidence of association between two NET single-nucleotide polymorphisms with ADHD. Mol Psychiatry 13:624-630.
13. Kirley A, Lowe N, Hawi Z, Mullins C, Daly G, Waldman I, McCarron M, O'Donnell D, Fitzgerald M, Gill M. 2003. Association of the 480 bp DAT1 allele with methylphenidate response in a sample of Irish children with ADHD. Am J Med Genet Part B 121B(1):50-54.
14. Kooij JS, Boonstra AM, Vermeulen SH, Heister AG, Burger H, Buitelaar JK, Franke B. 2008. Response to methylphenidate in adults with ADHD is associated with a polymorphism in SLC6A3 (DAT1). Am J Med Genet Part B 147B(2):201-208.
15. Langley K, Turic D, Peirce TR, Mills S, Van Den Bree MB, Owen MJ, O'Donovan MC, Thapar A. 2005. No support for association between the dopamine transporter (DAT1) gene and ADHD. Am J Med Genet Part B 139B:7-10.
16. Makoff A, Pilling C, Harrington K, Emson P. 1996. Human metabotropic glutamate receptor type 7: Molecular cloning and mRNA distribution in the CNS. Brain Res Mol Brain Res 40(1):165-170.
17. Markowitz JS, Straughn AB, Patrick KS. 2003. Advances in the pharmacotherapy of attention-deficit-hyperactivity disorder: Focus on methylphenidate formulations. Pharmacotherapy 23(10):1281-1299.
18. McGough J, McCracken J, Swanson J, Riddle M, Kollins S, Greenhill L, Abikoff H, Davies M, Chuang S, Wigal T, et al. 2006. Pharmacogenetics of methylphenidate response in preschoolers with ADHD. J Am Acad Child Adolesc Psychiatry 45(11):1314-1322.
19. Mick E, Faraone SV. 2008. Genetics of attention deficit hyperactivity disorder. Child Adolesc Psychiatr Clin N Am 17(2):261-284.
20. Mick E, Biederman J, Spencer T, Faraone SV, Sklar P. 2006. Absense of association with DAT1 polymorphism and response to methylphendate in a sample of adults with ADHD. Am J Med Genet Part B 141B(8):890-894.
21. Okamoto N, Hori S, Akazawa C, Hayashi Y, Shigemoto R, Mizuno N, Nakanishi S. 1994. Molecular characterization of a new metabotropic glutamate receptor mGluR7 coupled to inhibitory cyclic AMP signal transduction. J Biol Chem 269(2):1231-1236.
22. Pe'er I, Yelensky R, Altshuler D, Daly MJ. 2008. Estimation of the multiple testing burden for genomewide association studies of nearly all common variants. Genet Epidemiol 32(4):381-385.
23. Polanczyk G, Zeni C, Genro JP, Guimaraes AP, Roman T, Hutz MH, Rohde LA. 2007. Association of the adrenergic alpha2A receptor gene with methylphenidate improvement of inattentive symptoms in children and adolescents with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 64(2):218-224.
24. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P, de Bakker PI, Daly MJ, et al. 2007. PLINK: A tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81(3):559-575.
25. Roman T, Szobot C, Martins S, Biederman J, Rohde LA, Hutz MH. 2002. Dopamine transporter gene and response to methylphenidate in attention-deficit/hyperactivity disorder. Pharmacogenetics 12(6):497-499.
26. Stein MA, McGough JJ. 2008. The pharmacogenomic era: Promise for personalizing attention deficit hyperactivity disorder therapy. Child Adolesc Psychiatr Clin N Am 17(2):475-490, xi-xii.
27. Stein MA, Waldman ID, Sarampote CS, Seymour KE, Robb AS, Conlon C, Kim SJ, Cook EH. 2005. Dopamine transporter genotype and methylphenidate dose response in children with ADHD. Neuropsychopharmacology 30:1374-1382.
28. Tahir E, Yazgan Y, Cirakoglu B, Ozbay F, Waldman I, Asherson PJ. 2000. Association and linkage of DRD4 and DRD5 with attention deficit hyperactivity disorder (ADHD) in a sample of Turkish children. Mol Psychiatry 5(4):396-404.
29. Turic D, Langley K, Mills S, Stephens M, Lawson D, Govan C, Williams N, Van Den Bree M, Craddock N, Kent L, et al. 2004. Follow-up of genetic linkage findings on chromosome 16p13: Evidence of association of N-methyl-D aspartate glutamate receptor 2A gene polymorphism with ADHD. Mol Psychiatry 9(2):169-173.
30. Valera EM, Faraone SV, Murray KE, Seidman LJ. 2007. Meta-analysis of structural imaging findings in attention-deficit/hyperactivity disorder. Biol Psychiatry 61(12):1361-1369.
31. van der Meulen EM, Bakker SC, Pauls DL, Oteman N, Kruitwagen CL, Pearson PL, Sinke RJ, Buitelaar JK. 2005. High sibling correlation on methylphenidate response but no association with DAT1-10R homozygosity in Dutch sibpairs with ADHD. J Child Psychol Psychiatry 46(10):1074-1080.
32. Van Tol HH, Wu CM, Guan HC, Ohara K, Bunzow JR, Civelli O, Kennedy J, Seeman P, Niznik HB, Jovanovic V. 1992. Multiple dopamine D4 receptor variants in the human population. Nature 358(6382):149-152.
33. VanNess SH, Owens MJ, Kilts CD. 2005. The variable number of tandem repeats element in DAT1 regulates in vitro dopamine transporter density. BMC Genet 6:55.
34. Winsberg BG, Comings DE. 1999. Association of the dopamine transporter gene (DAT1) with poor methylphenidate response. J Am Acad Child Adolesc Psychiatry 38(12):1474-1477.
35. Yang Y, Hwang CK, D'Souza UM, Lee SH, Junn E, Mouradian MM. 2000. Three-amino acid extension loop homeodomain proteins Meis2 and TGIF differentially regulate transcription. J Biol Chem 275(27):20734-20741.
36. Yang L, Wang Y, Li J, Faraone SV. 2004. Association of norepinephrine transporter gene with methylphenidate response. J Am Acad Child Adolesc Psychiatry 43(9):1154-1158.
37. Zeni CP, Guimaraes AP, Polanczyk GV, Genro JP, Roman T, Hutz MH, Rohde LA. 2007. No significant association between response to methylphenidate and genes of the dopaminergic and serotonergic systems in a sample of Brazilian children with attention-deficit/hyperactivity disorder Am J Med Genet Part B 144B(3):391-394.